Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis

201966 citationsJournal Articlebronze Open Access

Authors

Moa P. Lee · University of North Carolina at Chapel Hill

Rishi Desai · Harvard University

Yinzhu Jin · Harvard University

Gregory Brill · Harvard University

Alexis Ogdie · University of Pennsylvania

Seoyoung C. Kim · Brigham and Women's Hospital

Abstract

No substantially different risk of incident AF or MACE after initiation of ustekinumab vs TNFi was observed in this study. This information may be helpful when weighing the risks and benefits of various systemic treatment strategies for psoriatic disease.

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies

Publication Details

Published in: JAMA Dermatology

Volume 155, Issue 6, pp. 700-700

DOI: 10.1001/jamadermatol.2019.0001

Field-Weighted Citation Impact: 3.32

Command Palette

Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis

Authors

Abstract

Topics & Keywords

Publication Details